Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Data from NCX 470 Phase 3 studies to be presented at 2026 AGS

February 10, 2026

What is the news ?

Nicox announces that Phase 3 data for NCX 470, including two podium presentations and one poster, will be presented at the 2026 American Glaucoma Society Annual Meeting.

What does it mean ?

The selection of these presentations highlights the scientific importance of the NCX 470 data and supports the product’s upcoming regulatory submissions in the United States and China.

What are the next steps ?

The Phase 3 results are scheduled to be presented at the AGS meeting on February 19–22, 2026, as Nicox and its partners advanced regulatory filings for NCX 470.
View Press Release Corporate presentation Contact us
Previous
Next